NASDAQ:TECX Tectonic Therapeutic (TECX) Stock Price, News & Analysis $20.34 +0.39 (+1.95%) Closing price 04:00 PM EasternExtended Trading$20.36 +0.02 (+0.10%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Tectonic Therapeutic Stock (NASDAQ:TECX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Tectonic Therapeutic alerts:Sign Up Key Stats Today's Range$19.74▼$20.5450-Day Range$19.95▼$37.7152-Week Range$15.52▼$39.53Volume226,969 shsAverage Volume258,263 shsMarket Capitalization$397.65 millionP/E RatioN/ADividend YieldN/APrice Target$69.17Consensus RatingModerate Buy Company Overview Tectonic Therapeutic, Inc. is a clinical-stage biotechnology company focused on developing medicines that target G protein-coupled receptors (GPCRs), a large class of cell-surface proteins involved in numerous biological processes and diseases. The company seeks to address GPCRs that have historically been difficult to target with conventional drug-discovery methods. Tectonic Therapeutic uses its proprietary GEODe platform to identify and develop antibodies and other biologic medicines against GPCRs. The platform is designed to help discover therapeutically relevant binding sites on these receptors and support the development of treatments for serious diseases, including potential applications in cardiovascular, immunological and other therapeutic areas. Based in the United States, Tectonic Therapeutic is advancing a pipeline of investigational programs and does not yet market approved commercial products. Its research and development activities are intended to support potential treatments for patients in global markets, subject to successful clinical development and regulatory review.AI Generated. May Contain Errors. Read More Tectonic Therapeutic Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks63rd Percentile Overall ScoreTECX MarketRank™: 3.14597315436 of 5 starsTectonic Therapeutic scored higher than 63% of companies evaluated by MarketBeat, and ranked 347th out of 905 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingTectonic Therapeutic has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 2 strong buy ratings, 5 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialTectonic Therapeutic has a consensus price target of $69.17, representing about 240.1% upside from its current price of $20.34.Amount of Analyst CoverageTectonic Therapeutic has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Tectonic Therapeutic's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Tectonic Therapeutic are expected to decrease in the coming year, from ($5.27) to ($5.70) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Tectonic Therapeutic is -4.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Tectonic Therapeutic is -4.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTectonic Therapeutic has a P/B Ratio of 1.51. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Tectonic Therapeutic's valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted18.90% of the float of Tectonic Therapeutic has been sold short.Short Interest Ratio / Days to CoverTectonic Therapeutic has a short interest ratio ("days to cover") of 10.58, which indicates bearish sentiment.Change versus previous monthShort interest in Tectonic Therapeutic has recently increased by 0.11%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTectonic Therapeutic does not currently pay a dividend.Dividend GrowthTectonic Therapeutic does not have a long track record of dividend growth. News and Social Media4.3 / 5News Sentiment0.96 News SentimentTectonic Therapeutic has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.69 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Tectonic Therapeutic this week, compared to 1 article on an average week.Search Interest1 people have searched for TECX on MarketBeat in the last 30 days. MarketBeat Follows1 people have added Tectonic Therapeutic to their MarketBeat watchlist in the last 30 days. Company Ownership2.1 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Tectonic Therapeutic insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $15,425.00 in company stock.Percentage Held by Insiders39.80% of the stock of Tectonic Therapeutic is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions62.63% of the stock of Tectonic Therapeutic is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Tectonic Therapeutic's insider trading history. Receive TECX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tectonic Therapeutic and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TECX Stock News HeadlinesTectonic Therapeutic, Inc. (TECX) - What Are Analysts Saying About This Stock?October 21, 2026 | americanbankingnews.comTectonic Therapeutic (NASDAQ:TECX) Stock Moved Down to Strong Sell by Wall Street ZenOctober 18, 2026 | americanbankingnews.comA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live.October 27 at 1:00 AM | Porter & Company (Ad)Analysts Offer Insights on Healthcare Companies: Tectonic Therapeutic (TECX), Boston Scientific (BSX) and Liquidia Technologies (LQDA)October 15, 2026 | theglobeandmail.comAnalysts Offer Insights on Healthcare Companies: Tectonic Therapeutic (TECX) and Solid Biosciences (SLDB)October 1, 2026 | theglobeandmail.comTectonic Therapeutic Says TX2100 Phase 1a Trial Met Primary ObjectivesSeptember 29, 2026 | finance.yahoo.comTectonic Therapeutic Announces Favorable Phase 1 Safety, Tolerability and PK Results for TX2100, a Novel Approach for the Treatment of Hereditary Hemorrhagic Telangiectasia (HHT)September 29, 2026 | globenewswire.comTectonic Therapeutic to Participate in the Morgan Stanley Global Healthcare ConferenceSeptember 3, 2026 | globenewswire.comSee More Headlines TECX Stock Analysis - Frequently Asked Questions How have TECX shares performed this year? Tectonic Therapeutic's stock was trading at $20.86 at the start of the year. Since then, TECX stock has decreased by 2.5% and is now trading at $20.34. How were Tectonic Therapeutic's earnings last quarter? Tectonic Therapeutic, Inc. (NASDAQ:TECX) released its earnings results on Thursday, August, 6th. The company reported ($1.18) earnings per share for the quarter, beating analysts' consensus estimates of ($1.35) by $0.17. When did Tectonic Therapeutic IPO? Tectonic Therapeutic (TECX) raised $89 million in an IPO on Thursday, June 21st 2018. The company issued 5,247,958 shares at $16.00-$18.00 per share. How do I buy shares of Tectonic Therapeutic? Shares of TECX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings8/06/2026Today10/27/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 TECX's financial health is in the Yellow zone, according to TradeSmith. TECX has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:TECX Previous SymbolNASDAQ:TECX CIK1681087 Webwww.tectonictx.com Phone617-914-8420FaxN/AEmployees60Year FoundedN/APrice Target and Rating Average Price Target for Tectonic Therapeutic$69.17 High Price Target$93.00 Low Price Target$26.00 Potential Upside/Downside+240.1%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage10 Analysts Profitability EPS (Trailing Twelve Months)($4.57) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$74.15 million Net MarginsN/A Pretax MarginN/A Return on Equity-35.26% Return on Assets-33.59% Debt Debt-to-Equity RatioN/A Current Ratio22.29 Quick Ratio22.29 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$13.43 per share Price / Book1.51Miscellaneous Outstanding Shares19,550,000Free Float11,768,000Market Cap$397.65 million OptionableOptionable Beta3.28 Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:TECX) was last updated on 10/27/2026 by MarketBeat.com Staff. From Our Partners6 Men Secretly Changed America’s Money. Now It’s Happening AgainIn 1910, six powerful men secretly met to lay the groundwork for the Federal Reserve, reshaping America's fina...Banyan Hill Publishing | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredMy next big call (under $1)17,556% on KDA. 3,900% on PRE. 2,650% on OCEAN. Every single one of these was recommended to our community bef...Crypto 101 Media | SponsoredHe turned $12K into $1.65M without touching Apple or TeslaTim Sykes turned $12,415 in gift money into more than $1.65 million before graduating college, without trading...Tim Sykes | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | SponsoredDon't lose access to thisIan Cooper's guide, 'The $50-to-$500 Options Strategy,' is still available for free download, but not for long...TradeWins | SponsoredWhy Gerardo Del Real says wait before buying uranium stocksGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tectonic Therapeutic, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tectonic Therapeutic With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
